Uric Acid

Uric Acid

SCHEMBL653072

O=c1[nH]c(=O)c2[nH]c(=O)[nH]c2[nH]1.[Zn]

nearest known ligand 0.94

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GDA Q9Y2T3 2/20 0.94
ALDH1A1 P00352 4/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
HPGD P15428 2/20 0.46
CYP2C19 P33261 2/20 0.46
HSD17B10 Q99714 2/20 0.46
ALOX15 P16050 1/20 0.46
MAPT P10636 3/20 0.46
KDM4E B2RXH2 2/20 0.46
GAA P10253 1/20 0.46
PKM P14618 1/20 0.46
BRPF1 P55201 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
TYMP P19971 5/20 0.39
GSK3B P49841 1/20 0.39
BACE1 P56817 1/20 0.39
IDH1 O75874 1/20 0.39
CSNK2A2 P19784 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Uric Acid SCHEMBL3417988 0.97 GDA (1.00) GDAALDH1A1CYP1A2CYP2C9HPGD
Uric Acid SCHEMBL30062557 0.97 GDA (1.00) GDAALDH1A1CYP1A2CYP2C9HPGD
Uric Acid SCHEMBL7933 0.97 GDA (1.00) GDAALDH1A1CYP1A2CYP2C9HPGD
Uric Acid SCHEMBL1071965 0.94 GDA (0.94) GDAALDH1A1CYP1A2CYP2C9HPGD
Uric Acid SCHEMBL925499 0.94 GDA (0.94) GDAALDH1A1CYP1A2CYP2C9HPGD
Uric Acid SCHEMBL11423974 0.94 GDA (0.94) GDAALDH1A1CYP1A2CYP2C9HPGD
Uric Acid SCHEMBL196769 0.94 GDA (0.94) GDAALDH1A1CYP1A2CYP2C9HPGD
Uric Acid SCHEMBL2434620 0.94 GDA (0.94) GDAALDH1A1CYP1A2CYP2C9HPGD
Uric Acid SCHEMBL229866 0.94 GDA (0.94) GDAALDH1A1CYP1A2CYP2C9HPGD
Uric Acid SCHEMBL10631703 0.94 GDA (0.94) GDAALDH1A1CYP1A2CYP2C9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110343321-A A kind of PVC calcium-zinc composite stabilizing agent and its technological process of production 宿州市杰牌化学有限公司 2019-10-18 CN claimed
CN-110204712-A A kind of method of synthesis in solid state cyanuric acid-uracil complexing zinc salt 深圳市志海实业股份有限公司 2019-09-06 CN claimed
EP-1843822-A1 AN EMULSION COMPOSITION FOR WET WIPES CONTAINING A NON-IRRITATING SKIN HEALTH BENEFIT INGREDIENT AND THE PROCESS FOR MAKING SAID WET-WIPES The Procter and Gamble Company (US) 2007-10-17 EP claimed
WO-2006083980-A1 AN EMULSION COMPOSITION FOR WET WIPES CONTAINING A NON-IRRITATING SKIN HEALTH BENEFIT INGREDIENT AND THE PROCESS FOR MAKING SAID WET-WIPES THE PROCTER & GAMBLE COMPANY (US) 2006-08-10 WO claimed
US-20060171971-A1 Composition for wet wipes containing a non-irritating skin health benefit ingredient and the process for making THE PROCTER & GAMBLE COMPANY 2006-08-03 US claimed
CN-114402043-B Dispersion and coating composition comprising inorganic oxide particles and zinc cyanurate particles 日产化学株式会社 2023-06-30 CN disclosed
CN-116144213-A Dispersion comprising inorganic oxide particles and zinc cyanurate particles 日产化学株式会社 2023-05-23 CN disclosed
EP-2666458-B1 PRE-MIX FOR A NON-LATHERING PERSONAL CARE ARTICLE, THE ARTICLE HAVING THE FORM OF A SOLID FOAM PROCTER & GAMBLE (US) 2021-09-29 EP disclosed
EP-2666457-B1 Process for forming a non-lathering personal care article in the form of a dissolvable solid foam PROCTER & GAMBLE (US) 2020-06-17 EP disclosed
CN-110343321-A A kind of PVC calcium-zinc composite stabilizing agent and its technological process of production 宿州市杰牌化学有限公司 2019-10-18 CN disclosed
CN-110343321-A A kind of PVC calcium-zinc composite stabilizing agent and its technological process of production 宿州市杰牌化学有限公司 2019-10-18 CN disclosed
CN-106660973-B The manufacturing method of alkali formula cyanuric acid zinc powder and the manufacturing method of rustproof pigment composition 日产化学工业株式会社 2019-04-23 CN disclosed
EP-1496887-A1 PERSONAL CARE COMPOSITIONS COMPRISING A ZINC CONTAINING MATERIAL IN AN AQUEOUS SURFACTANT COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2005-01-19 EP disclosed
EP-1496899-A1 USE OF MATERIALS HAVING ZINC IONOPHORIC BEHAVIOR THE PROCTER & GAMBLE COMPANY (US) 2005-01-19 EP disclosed
US-20040191331-A1 Composition comprising particulate zinc materials having a defined crystallite size THE PROCTER & GAMBLE COMPANY 2004-09-30 US disclosed
WO-2004082648-A1 COMPOSITION COMPRISING PARTICULATE ZINC MATERIALS HAVING A DEFINED CRYSTALLITE SIZE THE PROCTER & GAMBLE COMPANY (US) 2004-09-30 WO disclosed
US-20040058855-A1 Use of materials having zinc ionophoric behavior THE PROCTOR & GAMBLE COMPANY 2004-03-25 US disclosed
US-20030215522-A1 Personal care compositions comprising a zinc containing material in an aqueous surfactant composition THE PROCTER & GAMBLE COMPANY 2003-11-20 US disclosed
WO-2003088965-A1 USE OF MATERIALS HAVING ZINC IONOPHORIC BEHAVIOR THE PROCTER & GAMBLE COMPANY (US) 2003-10-30 WO disclosed
WO-2003088957-A1 PERSONAL CARE COMPOSITIONS COMPRISING A ZINC CONTAINING MATERIAL IN AN AQUEOUS SURFACTANT COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2003-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058855-A1 Use of materials having zinc ionophoric behavior SLC30A6, SLC39A7, SLC30A7 GDA 1108/4885ALDH1A1 3065/4885CYP1A2 1597/4885
US-20040191331-A1 Composition comprising particulate zinc materials having a defined crystallite size PPOX, LPO, THOC2 GDA 4680/4885ALDH1A1 4521/4885CYP1A2 2954/4885
US-20030215522-A1 Personal care compositions comprising a zinc containing material in an aqueous surfactant composition SLC30A7, SLC39A7, SOD1 GDA 4065/4885ALDH1A1 4256/4885CYP1A2 4813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.